NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
pliantrx.comPliant Therapeutics is implementing a strategic realignment, including a workforce reduction of approximately 45% and other cost-saving measures, with completion expected by the end of the second quarter of 2025. The restructuring aims to extend the company’s cash runway to support ongoing and late-stage clinical trials, following the close-out of the BEACON-IPF trial. The realignment reflects a focus on operational efficiency amid increased R&D and administrative expenses.
management changePliant Therapeutics expects to release topline data from the BEACON-IPF Phase 2b/3 trial in the second quarter of 2025, crucial for the development of bexotegrast.
clinical readoutPliant Therapeutics is expected to complete its Phase 2 randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis (IPF) on September 30, 2025. The study evaluates two doses of bexotegrast in 360 participants, with or without background therapy such as nintedanib or pirfenidone. Bexotegrast is an investigational oral small molecule targeting integrins, aimed at reducing fibrosis in IPF.
trial completionPliant Therapeutics is conducting a Phase 1 clinical trial of PLN-101095 in combination with pembrolizumab for adults with advanced or metastatic solid tumors who have progressed or relapsed after prior pembrolizumab treatment. The study, which began in August 2023, is expected to complete by December 1, 2025. The trial aims to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. PLN-101095 is an investigational therapy targeting patients with resistance to pembrolizumab, a PD-1 inhibitor used in various cancers.
trial completionThe stockholder rights agreement adopted by Pliant Therapeutics will expire on March 11, 2026, unless earlier terminated as provided in the agreement.
other